I’m not anti-GLP-1. These drugs have changed lives. People who spent decades fighting their bodies finally got relief, and evidence of benefits beyond weight loss keeps growing. If a medication is helping you, nothing here is a reason to stop. But I’ve watched enough hype cycles to recognize the shape of one, and the GLP-1 story has started to feel familiar. I think the investment and cultural bubble around these drugs is closer to deflating than the headlines suggest. Here’s why.
I’ve been taking Mounjaro for over 6 months. It has helped me lower my blood sugar and lose weight, but to be honest, I’m tired of the side effects. The nausea can really play havoc with my quality of life, and to be honest, I’m losing weight mostly because I’ve been able to ride my bike 100 miles a week since moving back to Florida.
After talking with a couple of local pharmacists, I’ve learned that GLP-1 Rx prescriptions are slowing down considerably. The reasons are the same: cost, side effects, and the feeling that they’re stuck taking these drugs for a long time. I think the GLP-1 bubble will burst, though they will still be part of our lives. Here’s why…
1ne. When everything is a “GLP-1 play,” something’s off
A few years ago, you could add “GLP-1” to an earnings call and watch a stock twitch. Telehealth startups, compounding pharmacies, snack companies “pivoting” to GLP-1-friendly foods, gyms, even restaurants adding “GLP-1 menus.” When an entire economy reorganizes its marketing around one drug class, I get nervous. That’s usually the late stage of a story, when the narrative has outrun the numbers.
2wo. The math of “everyone will take it forever” is shaky
Much of the bullish case assumes huge numbers of people starting these drugs and staying on them for life. But real-world behavior is messier. Side effects, cost, supply hassles, and plain fatigue with weekly injections lead many people to stop within the first year or so. Weight often returns when they do. Companies priced in a flood of lifelong customers, and I’m skeptical that the flood is as deep or as loyal as projected.
3hree. Prices can’t stay where they are
Healthcare systems and employers are already feeling the strain. A drug that could theoretically be prescribed to a third of adults is a budget problem for every insurer and government on earth. Something gives: coverage gets restricted, negotiated prices drop, or employers quietly drop the benefit. Each outcome squeezes the revenue valuations depend on.
4our. Competition is coming for the margins
The early leaders had a near-duopoly and enormous pricing power. That’s ending. More competitors are racing in with oral versions, next-generation injectables, and cheaper alternatives. Lots of competition is great for patients and terrible for anyone who bought in expecting today’s margins to last forever. Success attracts rivals, and rivals erode profits.
5ive. The “miracle” story is getting more complicated
The more people use these drugs, the more we learn about the tradeoffs: muscle loss, digestive problems, what happens when people stop, and questions we don’t have decades of data to answer. None of this makes the drugs bad. But a miracle story is fragile, and reality is rarely as clean as the marketing. When the narrative shifts from “miracle” to “useful tool with real tradeoffs,” expectations, and prices tend to reset.
6ix. Culture always overcorrects
I’ve also noticed a shift in mood. A year or two ago, the conversation was breathless. Now there’s a growing backlash: people tired of the shortcuts-versus-willpower debate, worried about long-term dependence, or just sick of hearing about it. Bubbles don’t pop only because of spreadsheets. They pop when the story loses its shine.
What “bursting” actually means
I want to be clear about what I’m predicting. I don’t think GLP-1 drugs vanish. They’ll likely become a normal, permanent part of medicine, a bit like statins. But “normal and permanent” is a very different thing from “the greatest growth story in history.” A bubble bursting doesn’t mean the underlying thing was fake. The internet didn’t disappear in 2000. It just stopped being priced like a lottery ticket.
So my guess is that we’ll see a correction: lower prices, tighter coverage, thinner margins, and a few too-clever companies learning that attaching themselves to a trend isn’t a business model.
The other side
To be fair, plenty of thoughtful people disagree. Their case is that obesity and related disease are so widespread, and these drugs so effective, that demand will keep outrunning supply for years. They point to new uses being studied, from heart and kidney health to other conditions, and argue that falling prices will expand the market rather than shrink it. They may well be right. I’m giving you my read, not a prophecy.
And if you’re an investor, please don’t take stock advice from a blog post. I’m not a financial advisor, and neither is anyone’s gut feeling. If you’re a patient, talk to your doctor before changing anything.

